GE Healthcare
Driving Innovation

Tom Gentile
President & CEO
GE Healthcare Systems

Morningstar
Management Behind the Moat Conference
7 November 2013
Caution Concerning Forward-Looking Statements:
This document contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: current economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices and the value of financial assets; potential market disruptions or other impacts arising in the United States or Europe from developments in sovereign debt situations; the impact of conditions in the financial and credit markets on the availability and cost of General Electric Capital Corporation’s (GECC) funding and on our ability to reduce GECC’s asset levels as planned; the impact of conditions in the housing market and unemployment rates on the level of commercial and consumer credit defaults; changes in Japanese consumer behavior that may affect our estimates of liability for excess interest refund claims (GE Money Japan); pending and future mortgage securitization claims and litigation in connection with WMC, which may affect our estimates of liability, including possible loss estimates; our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so; the adequacy of our cash flow and earnings and other conditions which may affect our ability to pay our quarterly dividend at the planned level or to repurchase shares at the planned level; GECC’s ability to pay dividends to GE at the planned level; our ability to convert pre-order commitments into orders; the level of demand and financial performance of the major industries we serve, including, without limitation, air and rail transportation, energy generation, real estate and healthcare; the impact of regulation and regulatory, investigative and legal proceedings and legal compliance risks, including the impact of financial services regulation; our capital allocation plans, as such plans may change and affect planned share repurchases and strategic actions, including acquisitions, joint ventures and dispositions; our success in completing announced transactions and integrating acquired businesses; the impact of potential information technology or data security breaches; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

“This document may also contain non-GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For a reconciliation of non-GAAP measures presented in this document, see the accompanying supplemental information posted to the investor relations section of our website at www.ge.com.”

“In this document, “GE” refers to the Industrial businesses of the Company including GECC on an equity basis. “GE (ex. GECC)” and/or “Industrial” refer to GE excluding Financial Services.”

GE’s Investor Relations website at www.ge.com/investor and our corporate blog at www.gereports.com, as well as GE’s Facebook page and Twitter accounts, contain a significant amount of information about GE, including financial and other information for investors. GE encourages investors to visit these websites from time to time, as information is updated and new information is posted.
GE Healthcare

~$20 billion global business unit of GE

53,000 employees worldwide

~$1 billion/year investment in R&D

Leadership businesses

Healthy imagination focused on:

Affordability  Improved quality  Increased access

Healthcare Systems

Main products
CT  DGS
MR  U/S
MI  LCS
Services
Rev.  $14B

Healthcare IT

Main products
PACS
RIS
Ambulatory EMR
Caradigm (MS JV)
Rev.  $2B

Life Sciences

Main products
Bioprocess
Cell technologies
Research
Consumables
PET/SPECT Tracers
Clarinet/Pathology
Genomics
Rev.  $4B

At work for a healthier world ...
Despite continuing pressure on healthcare costs, we see positive opportunities

Other trends creating significant opportunity

Accelerating globalization

<table>
<thead>
<tr>
<th>HCS Sales</th>
<th>($ in millions)</th>
<th>CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emerging</td>
<td>20%</td>
<td>15%</td>
</tr>
<tr>
<td>Developed</td>
<td>80%</td>
<td>3%</td>
</tr>
</tbody>
</table>

Growing cancer screening

<table>
<thead>
<tr>
<th>Cumulative Screening Initiatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>60</td>
</tr>
</tbody>
</table>

Growing MIS

<table>
<thead>
<tr>
<th>Global procedures in millions</th>
<th>CAGR &gt;10%</th>
</tr>
</thead>
<tbody>
<tr>
<td>07</td>
<td>'16E</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Screen &amp; Diagnose</th>
<th>Treat</th>
<th>Monitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Segment $B</td>
<td>20</td>
<td>25</td>
</tr>
<tr>
<td>Growth %</td>
<td>5%</td>
<td>15%</td>
</tr>
<tr>
<td>CM %</td>
<td>40%</td>
<td>60%</td>
</tr>
</tbody>
</table>

Growing Molecular Dx

<table>
<thead>
<tr>
<th>Clinical molecular Dx segment</th>
<th>($ in billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>$0.36</td>
</tr>
<tr>
<td>2000</td>
<td>$0.94</td>
</tr>
<tr>
<td>2005</td>
<td>$2.7</td>
</tr>
<tr>
<td>2009</td>
<td>$3.65</td>
</tr>
<tr>
<td>2012</td>
<td>$5.3</td>
</tr>
</tbody>
</table>

Source: Kalorama Information
Global healthcare structural dynamics

Healthcare spend by country

Growing healthcare % of GDP...multiplier effect

Very high spend...GDP growth at best

+15%

+3%

Source: World Bank

New growth less concentrated, more complex
Anesthesia delivery system in Africa

Current Situation

- Two physicians for every 10,000 people
- 0.4 hospital beds per 1000 people.
- Poorest ~35% receive only 3.5% of all surgeries
- 99% of maternal deaths in resource poor countries
- Average of 1 maternal death per 100 live births.
- Anesthesia tremendous risk in developing countries
- UK has 400x more anesthesiologist than Uganda

Technology & Rationale

Carestation 30

- Launched in Kenya on November 12, 2012
- Created specifically for developing countries
- Cost =~$10,000 (varies by location & configuration)
- Enhanced capabilities – Integrated Sp02
- Compact breathing system to minimize leaks
- Battery lasts up to 6 hours
- Clinical education and training program

Advancing safe surgery in Africa
Vscan™ – Pocket-sized ultrasound

Description
• Pocket-sized, hand held ultrasound

Benefits
• Variety of clinical applications
• Immediate visualization
• Up to 1 hour continuous scanning capability
• Simplified presets for Abdominal, Cardiac & OB

GE Difference
• Currently the only device this size with these features at this price point

A leader in pocket-sized ultrasound
Ultrasound pregnancy exam

Check five basic conditions with a V-scan and refer to higher level of care

- Muliple births
- Breach
- Gestational Age
- Placenta Previa
- Cord issues

Indonesia

Ghana

Millennium development goals 4 & 5:
Reduce maternal and infant mortality

Muliple births

Breach

Gestational Age

Placenta Previa

Cord issues

Check five basic conditions with a V-scan and refer to higher level of care
Breast Cancer

Leading cause of cancer in women... ~ 500K deaths per annum

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Death Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>458</td>
</tr>
<tr>
<td>Lung</td>
<td>427</td>
</tr>
<tr>
<td>Colon</td>
<td>288</td>
</tr>
<tr>
<td>Cervix</td>
<td>275</td>
</tr>
<tr>
<td>Stomach</td>
<td>273</td>
</tr>
</tbody>
</table>

* Cancer deaths per thousand patients

Aging and increased access driving global procedures

Cumulative Screening

- Breast
- Colon
- Cervix

Mortality reductions small, but quality of life years extension high

Type of Disease
- e.g., Luminal A, Luminal B, HER2+, Triple neg

Risk Factors
- e.g., family history

Physiology
- e.g., dense breasts

Most frequent cancer in women – over one million new diagnosis / year

* Source: WHO, 2008
GE plays across breast care continuum

“Connecting” across modalities

- FFDM
- DBT
- CESM
- Other
- U/S
- MRI
- MBI
- PET/CT
- MDX
- Clariant
- IT

Hardware

Wetware

Services

Software

Screening | Diagnosis | Staging | Treatment Planning | Monitoring

**Meet Grace**
This is her story

- FFDM
- DBT
- CESM
- Other

**U/S**
- Automated Breast Ultrasound

**MDX**
- Visipaque*, Omnipaque*, Omniscan*, Sonozoid*, Nanocol*

**Clariant**
- IDI AW PACS ViewPoint
- IDI AW PACS ViewPoint Xeleris
- PATHSiTE, Omnyx**
- Virtual Tumor Board

- Current
- Planned

* No FDA organ-specific indications for breast
** Product under development. Omnyx products are for research only. Not for use in diagnostic procedures.
Scalpelless surgery becoming a reality
MR guided focused ultrasound by InSightec, Ltd.

Non-invasive ablation, high energy ultrasound

Regulatory Procedure Approvals
- 2006 – FDA Uterine fibroids
- 2012 – FDA Bone metastasis
- 2013 - UF CFDA, Brazil, Canada
  Bone Brazil, Canada
  FDA Stage 3 ET Trial
  FDA Stage 1 Prostate

Recent Developments
- Essential tremor study published in New England Journal of Medicine, August, 2013

Comm’l Procedures +18% annually

Non-invasive MR guided surgery
Precision medicine

A century of ‘mass market’ medicine comes to an end...

Global 2015 Estimates

- $600B (Secondary Convergence PM Market)
- $195B
  - Oncology
  - Research Investment
  - Public Health
  - Targeted Rx
  - Clinical Services
- $15B
  - CVD & Neurosciences
- $120B
  - Social Media / Networks
  - TeleHealth

$800B Market

Moving to ‘personalized’ patient-based decisions

Theme: Precision Medicine across the continuum of care

- Screening
- Diagnosis
- Staging
- Treatment Planning
- Monitoring

- Am I at risk for a disease?
- Do I have a disease?
- What type of disease do I have?
- Should I actively treat my disease?
- Is my disease responding to treatment?
- What further action should I take?

Aligning care around personal factors

- Physiology
- Risk Factors
- Type of disease

Opportunities from advancements in imaging/multi-omics

- CESM
- Molecular Platforms
- Biomarker Assessment
Monitoring therapies

Quantitative PET – Q.Suite Platform

- Consistent SUV measurements of metabolic activity
- Eight capabilities working together
- Designed to aid in the early determination of treatment effectiveness

Built from collaborations between clinical research partners and GE scientists

Many breakthrough technologies only available from GE Healthcare
Our purpose... a reminder

At work for a healthier world